肺癌质子治疗患者选择:2年死亡率预后模型的全国外部验证与更新
该研究对含平均心脏剂量、大体肿瘤体积和吸烟状态的预后模型进行全国多中心外部验证,用于筛选局部晚期NSCLC接受(放)化疗后2年死亡风险。5中心1094例中554例(51%)2年内死亡,最终模型区分度中等(AUC 0.64),校准良好,已被国家卫生机构采纳用于质子治疗模型化选择与报销。
要点
- 模型含平均心脏剂量、大体肿瘤体积和吸烟,预测2年全因死亡。
- 外部验证显示各中心间性能一致,AUC 0.64,校准良好。
- 已被国家卫生机构用于肺癌质子治疗的模型化选择与报销。
核心结论
- 该全国外部验证研究形成的2年死亡率预后模型在各中心患者队列中表现一致。
- 模型已被国家卫生机构采纳用于肺癌质子治疗的模型化选择与报销。
研究设计与样本
- 对已发表的含平均心脏剂量、大体肿瘤体积和吸烟的预后模型进行外部验证与更新,队列来自5个中心。
- 采用区分度和校准评估模型性能,必要时行内部-外部交叉验证(IECV)。
- 使用岭回归在合并数据集拟合最终预测因子,并用自助法进行进一步内部验证。
主要发现
- 共1094例中554例(51%)在2年内死亡。
- 预后模型性能在各中心间差异明显,但IECV显示三项性能指标的异质性很低,提示性能跨中心一致。
- 最终模型含平均心脏剂量和大体肿瘤体积,区分度中等(AUC 0.64;95%CI 0.61-0.68)。
- 校准良好:校准-in-the-large为0.0(-0.12-0.12),校准斜率为1.04(0.78-1.30)。
关键数值与推荐
- 模型预测对象为接受(放)化疗的不可切除局部晚期NSCLC患者的2年全因死亡率。
- 最终模型预测因子包括平均心脏剂量和大体肿瘤体积。
- 区分度AUC 0.64(95%CI 0.61-0.68),校准-in-the-large 0.0(-0.12-0.12),校准斜率1.04(0.78-1.30)。
临床怎么用
- 可用于局部晚期NSCLC患者质子治疗前的模型化选择,辅助识别2年死亡风险。
- 模型已被国家卫生机构用于质子治疗选择与报销决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To externally validate a prognostic model for the prediction of 2-year mortality in locally advanced non-small cell lung cancer (NSCLC) patients treated with (chemo)radiotherapy in multiple Dutch centers, to enable selection of patients for proton therapy. MATERIALS AND METHODS: A published prognostic model for 2-year all-cause mortality after (chemo)radiotherapy for irresectable NSCLC, including mean heart dose, gross tumor volume, and smoking, was selected. External validation and model update was performed on cohorts from 5 centers. Model performance was assessed in terms of discrimination and calibration. In case the model performance differed substantially across centers, this was followed by an internal-external cross-validation (IECV) procedure. Ridge regression was used to fit the final set of predictors to the combined dataset and bootstrapping was applied to perform further internal validation. RESULTS: A total of 554/1094 (51 %) patients died within 2 years. Performance of the prognostic model differed substantially across centers. The IECV showed very low levels of heterogeneity in all three performance measures, indicating performance was consistent across centers. The final model, including the mean heart dose and gross tumor volume, showed moderate discrimination (AUC 0.64; 95 %CI 0.61-0.68) and good calibration (calibration-in-the-large 0.0; -0.12-0.12, calibration slope 1.04 [0.78-1.30]). CONCLUSION: This nation-wide external validation study of a prognostic model for 2-year mortality resulted in a model that performs consistently in patient cohorts across the country. The model has been adopted by the national health authority for model-based selection and reimbursement of proton therapy for lung cancer.
引用
- van Loon J, Wijsman R, Boersma L, et al. Patient selection for proton therapy in lung cancer: Nationwide external validation and model update of a prognostic model for 2-year mortality including mean heart dose. Radiother Oncol. 2025. PMID: 41192769. doi:10.1016/j.radonc.2025.111257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。